EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Mediar Therapeutics
- Study ID
- NCT07287670
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Diffuse Cutaneous Systemic Sclerosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MTX-474 — BIOLOGICALDosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc).
- Placebo — OTHERPlacebo
Study Details
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Key Dates
- First listed
- Dec 17, 2025
- Start date
- Apr 16, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 85 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: MTX-474MTX-474
- Placebo Comparator: PlaceboPlacebo
Primary Outcome Measure
Change from baseline in Modified Rodnan Skin Score (mRSS) [ Time Frame: Baseline to week 24 ]
Central Contacts
- Jeffrey Bornstein, MD(617) 936-0960
Locations (23)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| EncompaSSc site in Phoenix, AZ | Phoenix | Arizona | 85054 | |
| EncompaSSc site in La Jolla, CA | La Jolla | California | 92037 | |
| EncompaSSc site in Loma Linda, CA | Loma Linda | California | 92350 | |
| University of California Los Angeles Scleroderma Center | Los Angeles | California | 90095 | Elizabeth Volkmann (PRINCIPAL_INVESTIGATOR) |
| NewportNativeMD, Inc. | Newport Beach | California | 92663 | Ryan Klein (PRINCIPAL_INVESTIGATOR) |
| EncompaSSc site in Palo Alto, CA | Palo Alto | California | 94304 | |
| University of Colorado Center for Lungs/Breathing/Scleroderma Clinic | Aurora | Colorado | 80045 | Melissa Griffith (PRINCIPAL_INVESTIGATOR) |
| Clinical Research of West Florida | Clearwater | Florida | 33765 | Rodney Daniel (PRINCIPAL_INVESTIGATOR) |
| EncompaSSc site in Sarasota, FL | Sarasota | Florida | 34239 | |
| Clinical Research of West Florida | Tampa | Florida | 33606 | John Carter (PRINCIPAL_INVESTIGATOR) |
| EncompaSSc site in Kansas City, KS | Kansas City | Kansas | 66103 | |
| Johns Hopkins University | Baltimore | Maryland | 21205 | Laura Hummers (PRINCIPAL_INVESTIGATOR) |
| Boston Medical Center | Boston | Massachusetts | 02118 | Andreea Bujor (PRINCIPAL_INVESTIGATOR) |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Avery LaChance (PRINCIPAL_INVESTIGATOR) |
| EncompaSSc site in Minneapolis, MN | Minneapolis | Minnesota | 55455 | |
| EncompaSSc site in Brooklyn, NY | Brooklyn | New York | 11201 | |
| EncompaSSc site in Cleveland, OH | Cleveland | Ohio | 44195 | |
| EncompaSSc site in Oklahoma City, OK | Oklahoma City | Oklahoma | 73104 | |
| EncompaSSc site in Philadelphia, PA | Philadelphia | Pennsylvania | 19107 | |
| EncompaSSc site in Pittsburgh, PA | Pittsburgh | Pennsylvania | 15219 | |
| Stryde Research - DFW | Allen | Texas | 75013 | John Lavery (PRINCIPAL_INVESTIGATOR) |
| Baylor Scott & White Research Institute | Dallas | Texas | 75246 | Susan Mathai (PRINCIPAL_INVESTIGATOR) |
| EncompaSSc site in Houston, TX | Houston | Texas | 77030 |
Find similar trials in Phoenix, AZ
By research site
Related Studies
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisPHASE2 · Recruiting · Novartis Pharmaceuticals · Mesa, Arizona
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseasePHASE1 · Recruiting · CRISPR Therapeutics · Redwood City, California
- US Zamto-cel Autoimmune DiseasesPHASE1 · Recruiting · Miltenyi Biomedicine GmbH · Milwaukee, Wisconsin